FIGS insider filing: tax sale disclosed; major option repricing lowers strike to $6.63
Rhea-AI Filing Summary
FIGS insider transaction summary: Catherine Spear, the company's CEO, director and a 10% owner, reported on Form 4 that 65,866 shares of Class A Common Stock were sold on August 13, 2025 at $6.88 per share solely to cover taxes and fees arising from RSU vesting pursuant to a 10b5-1 instruction. Following that sale, Ms. Spear beneficially owned 1,969,246 shares of Class A Common Stock directly and indirectly, plus significant additional holdings not reported on this Form 4, including 5,469,161 Class B shares convertible into Class A and 18,958,606 shares underlying vested options.
Separately, on August 12, 2025 the company completed a one-time option repricing affecting 727,097 fully vested options originally granted May 26, 2021: the exercise price was reduced from $22.00 to $6.63, and the repriced options now vest in 24 equal monthly installments beginning September 12, 2025; expiration dates and share counts remain unchanged.
Positive
- Sale disclosed as 10b5-1 tax-covering transaction, indicating the 65,866-share sale was executed solely to pay taxes and fees on RSU vesting
- Full disclosure of holdings including direct Class A ownership and details on Class B convertible shares and option counts provides transparency
Negative
- Option repricing materially reduced exercise price from $22.00 to $6.63 for 727,097 options, increasing intrinsic value and potential dilution
- Vesting schedule extended for repriced options which alters compensation dynamics despite no change to expiration or share count
Insights
TL;DR: Insider sold shares only to cover taxes; large option repricing materially lowers exercise price and alters vesting.
The reported sale of 65,866 Class A shares at $6.88 was executed under a 10b5-1 instruction solely to satisfy tax and fee obligations from RSU settlement, which reduces the likelihood the sale reflects a change in view on company fundamentals. The Option Repricing reducing exercise price from $22.00 to $6.63 on 727,097 options is material: it increases the immediate intrinsic value of those option holders and creates potential dilution upon exercise. Vesting was extended into 24 monthly installments starting September 12, 2025, which staggers potential option exercises. Investors should note the company disclosed substantial additional convertible and option-based share exposure elsewhere in the filing.
TL;DR: Option repricing raises governance and alignment questions despite tax-covering sale disclosure.
The one-time repricing of 727,097 fully vested options to the then-closing price of $6.63 represents a significant concession to option holders and may be perceived as management-favoring, as it materially increases the value available to insiders relative to the original $22.00 strike. While vesting extension introduces future service requirements, the combination of lowering exercise price and retaining original expiration and share counts warrants scrutiny from a governance perspective because it can dilute existing shareholders and changes executive compensation economics. The disclosed 10b5-1 tax-sale is routine and transparently reported.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Class A Common Stock | 65,866 | $6.88 | $453K |
| Disposition | Stock Option (Right to Buy) | 727,097 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 727,097 | $0.00 | -- |
| holding | Class A Common Stock | -- | -- | -- |
| holding | Class A Common Stock | -- | -- | -- |
Footnotes (1)
- REPRESENTS THE AGGREGATE NUMBER OF SHARES SOLD BY THE REPORTING PERSON SOLELY TO COVER REQUIRED TAXES AND FEES DUE UPON THE VESTING AND SETTLEMENT OF RESTRICTED STOCK UNITS ("RSUs"). THE SALES WERE MADE PURSUANT TO A 10B5-1 INSTRUCTION LETTER DELIVERED TO THE ISSUER ON MAY 13, 2025, AND NONE OF THE SHARES REPORTED AS SOLD ON THIS FORM 4 WERE SOLD FOR ANY REASON OTHER THAN TO COVER REQUIRED TAXES AND FEES. 1,460,886 of these securities are RSUs, each representing a contingent right to receive one share of the Issuer's Class A Common Stock. In addition to the securities reported in this column, the Reporting Person holds 5,469,161 shares of the Issuer's Class B Common Stock directly and indirectly through various trusts, which are convertible at any time at the option of the Reporting Person into an equal number of shares of Class A Common Stock, and 18,958,606 shares of the Issuer's Class A Common Stock underlying vested options, neither of which are reported on this Form 4. The Reporting Person is a managing member of Hollywood Capital Partners LLC and disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein. All shares underlying this option have vested. The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 12, 2025 (the "Repricing Date"). The Option Repricing applies to 727,097 fully vested options originally granted to the Reporting Person on May 26, 2021 with an original exercise price of $22.00. Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $6.63 per share, the closing price of the Issuer's Class A Common Stock on the Repricing Date. The vesting schedule of the repriced options has also been extended as reported herein. There is no change to the expiration date of, or number of shares underlying, the repriced options. For more information, see Part II, Item 5. "Other Information" in the Issuer's Form 10-Q filed with the SEC on August 7, 2025. The option vests and becomes exercisable in 24 equal monthly installments, with the first installment vesting on September 12, 2025.
